Authors
Latest:
Efficacy of PD-1/PD-L1 Inhibitors in MelanomaJason J. Luke, MD, FACP, assistant professor of medicine, The University of Chicago, discusses the efficacy of PD-1/PD-L1 inhibitors in melanoma.
Latest:
REALITIVTY-047 Study Design Shows Mature Response Results in MelanomaJason Luke, MD, discusses how the gated design of the REALITIVITY-047 led to results being delivered in phases for patients with advanced melanoma treated with the combination of relatlimab and nivolumab.
Latest:
Exploring Intratumoral Immunotherapy in Melanoma and Other MalignanciesJason Luke, MD, FACP, discusses promising clinical research around intratumoral immunotherapy.
Latest:
TNBC Vaccine Shows Promising Safety, Immune Response in Phase 1 TrialA phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety and tolerability.
Latest:
Next-Generation Sequencing in Intimal SarcomaDuring the 2018 Annual Meeting of the Connective Tissue Oncology Society, Jason Roszik, PhD, MBA, of the MD Anderson Cancer Center, discusses the use of next-generation sequencing in intimal sarcoma.<br />
Latest:
Rationalizing the Study of Intratumoral Immunotherapy in Breast Cancer Origin Liver MetastasesJason Williams, MD, the director of Interventional Oncology and Immunotherapy oncologist at the Williams Cancer Institute, discusses a study in which an immunotherapy combination was administered intratumorally to patients with liver metastases linked to breast cancer, which he presented in a poster at the 2019 Society of Immunotherapy of Cancer Annual Meeting.
Latest:
Current Treatment Landscape for CLLJavier Pinilla-Ibarz, MD, PhD, senior member of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the current treatment landscape of chronic lymphocytic leukemia.
Latest:
The Significance of Hematuria in Urothelial CarcinomaJay D. Raman, MD, professor of Surgery and chief of the Division of Urology at Penn State Milton S. Hershey Medical Center, discusses hematuria in patients with urothelial carcinoma.
Latest:
Dr. Jean Hoffman-Censits on the Future of Atezolizumab in Bladder CancerHoffman-Censits says atezolizumab has recently undergone a phase II clinical trial for patients with bladder cancer who failed platinum-based chemotherapy.
Latest:
Data Support Momelotinib as a Differentiated Approach to Treating MyelofibrosisJAK inhibitors designed for the treatment of myelofibrosis address the splenic response and constitutional symptoms associated with the disease, but the agents are inherently myelosuppressive and can exacerbate anemia and thrombocytopenia.
Latest:
Significance of Findings in RESPONSE Trial in Polycythemia VeraJean-Jaques Kiladjian, MD, PhD, discusses how the results from the RESPONSE trial impact patients with polycythemia vera.
Latest:
Disparities in Treating Head and Neck Cancer in WomenJed A. Katzel, MD, medical oncologist at Kaiser Permanente Santa Clara, discusses the findings from a study using a generalized competing event model to look at patients with head and neck cancer.
Latest:
A First In-Human Study of Novel PI3K Inhibitor IPI-549 in Patients With Advanced Solid TumorsJedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses a phase 1/1b first in-human study of IPI-549, a PI3K gamma inhibitor as monotherapy and in combination with pembrolizumab (Keytruda) in patients with advanced solid tumors.
Latest:
Dr. Jedd Wolchok Talks About the Phase III CheckMate 067 Trial and its Effects on Untreated Melanoma PatientsJedd D. Wolchok, MD, PhD, chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center in New York City, talks about the phase III CheckMate 067 trial.
Latest:
The Role of PD-1 Inhibitors in Liver CancerJeff Geschwind, MD, professor and chairman, Radiology and Biomedical Imaging, Yale Cancer Center, discusses the potential role that PD-1 inhibitors may play in the treatment of liver cancer.
Latest:
ELEVATE-TN Shows Acalabrutinib Is Well-Tolerated in CLLJeff P. <a>Sharman</a>, MD, discusses the safety profile of acalabrutinib that was demonstrated in <a href="https://www.targetedonc.com/conference/ash-2019/patients-with-cll-treated-on-the-elevatetn-trial-experience-improved-pfs-with-acalabrutinib"><strong>the phase III ELEVATE-TN trial</strong></a>. The trial evaluated acalabrutinib as a single agent or in combination with obinutuzumab versus obinutuzumab plus chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia.
Latest:
Acalabrutinib Appears Tolerable in Chronic Lymphocytic LeukemiaJeff P. Sharman, MD, discusses the secondary end points from the <u><strong><a href="https://www.targetedonc.com/conference/ash-2019/patients-with-cll-treated-on-the-elevatetn-trial-experience-improved-pfs-with-acalabrutinib">phase III ELEVATE-TN trial</a></strong></u>, which evaluated the role of acalabrutinib, either as a single agent or in combination with obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.
Latest:
Next Steps for Acalabrutinib/Obinutuzumab in Treatment-Naive CLLJeff Sharman, MD, discusses the clinical implications for oncologists based on data from the ELEVATE-TN trial.
Latest:
Checkpoint Inhibitors in Cancer CareJeffrey A. Sosman, MD, from the Vanderbilt University School of Medicine and Vanderbilt-Ingram Cancer Center, discusses the use of checkpoint inhibitors in cancer care.
Latest:
An Overview of the AM0010 Study in Kidney Cancer, Other CancersJeffrey Infante, MD, Director of Drug Development at Sarah Cannon, discusses findings of the AM0010 study.
Latest:
Proton Therapy for Recurrent GliomaJeffrey J. Raizer, MD, provides an overview of a study that analyzed the overall survival and toxicity profile of proton therapy for large-volume re-irradiation for patients with recurrent glioma.
Latest:
Dr. Jeffrey Jones on Idelalisib and Ibrutinib in Patients With CLLJeffrey Jones, MD, discusses treatment options for patients with chronic lymphocytic leukemia (CLL) who progress on, or become intolerant of, idelalisib or ibrutinib during their treatment.
Latest:
The Benefits of Venetoclax in CLLJeffrey Jones, MD, MPH, associate professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the benefits of venetoclax in chronic lymphocytic luekemia (CLL).
Latest:
Dr. Weitzel Discusses the Impact of Gene Mutations on TreatmentJeffrey N. Weitzel, MD, director, Clinical Cancer Genetics, director, Cancer Screening & Prevention Program Network, professor, City of Hope, discusses the impact of gene mutations on treatment.
Latest:
Dr. Jeffrey Infante on the Positive Results of Using Avelumab in Patients With Ovarian CancerJeffrey R. Infante, MD director of Drug Development, Sarah Cannon Research Institute, talks about the anti-PD-L1 antibody avelumab in patients with previously treated, recurrent or refractory ovarian cancer.
Latest:
Adverse Events With Dabrafenib/Trametinib Combination in MelanomaJeffrey S. Weber, MD, PhD, deputy director of the Perlmutter Cancer Center at NYU Langone Medical Center, discusses the adverse events commonly associated with the combination of dabrafenib and trametinib in the adjuvant setting for patients with BRAF V600E– or V600K–positive stage III melanoma.
Latest:
The Benefits of myPlan to Help Identify High-Risk Patients With NSCLCJeffrey Schneider, MD, chief of hematology and medical oncology, Winthrop University Hospital, discusses the benefits of Myriad's myPlan in determining high-risk patients with non-small cell lung cancer (NSCLC).
